Literature DB >> 26198700

Cyclin-dependent kinase 5 represses Foxp3 gene expression and Treg development through specific phosphorylation of Stat3 at Serine 727.

Eric Lam1, Sung Hee Choi2, Tej K Pareek2, Byung-Gyu Kim2, John J Letterio3.   

Abstract

Cyclin-dependent kinase 5 (Cdk5) is known as a unique member of the cyclin-dependent family of serine/threonine kinases. Previously, we demonstrated Cdk5 to be an important regulator of T cell function and that disruption of Cdk5 expression ameliorates T cell mediated neuroinflammation. Here, we show a novel role of Cdk5 in the regulation of Foxp3 expression in murine CD4(+) T cells. Our data indicate that disruption of Cdk5 activity in T cells abrogates the IL-6 suppression of Foxp3 expression. This effect is achieved through Cdk5 phosphorylation of the signal transducer and activator of transcription 3 (Stat3) specifically at Serine 727 in T cells, and we show this post-translational modification is required for proper Stat3 DNA binding to the Foxp3 gene on the enhancer II region. Taken together, our data point to an essential role for Cdk5 in the differentiation of T cells as it regulates Foxp3 gene expression through phosphorylation of Stat3.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyclin dependent kinase; Phosphorylation; Post-translational; Regulatory T cell; Signaling

Mesh:

Substances:

Year:  2015        PMID: 26198700      PMCID: PMC4734131          DOI: 10.1016/j.molimm.2015.06.015

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  26 in total

Review 1.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.

Authors:  Song Guo Zheng; J Dixon Gray; Kazuo Ohtsuka; Satoshi Yamagiwa; David A Horwitz
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

3.  Cdk5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex.

Authors:  Eric Lam; Tej K Pareek; John J Letterio
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Extraneuronal roles of cyclin-dependent kinase 5.

Authors:  Jesusa L Rosales; Ki-Young Lee
Journal:  Bioessays       Date:  2006-10       Impact factor: 4.345

5.  A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5).

Authors:  Anna Kaźmierczak; Grzegorz A Czapski; Agata Adamczyk; Barbara Gajkowska; Joanna B Strosznajder
Journal:  Neurochem Int       Date:  2010-12-02       Impact factor: 3.921

Review 6.  A decade of CDK5.

Authors:  R Dhavan; L H Tsai
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 7.  Cdk5: multitasking between physiological and pathological conditions.

Authors:  Joao P Lopes; Paula Agostinho
Journal:  Prog Neurobiol       Date:  2011-04-05       Impact factor: 11.685

8.  A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.

Authors:  Ya-Li Zheng; Bing-Sheng Li; Niranjana D Amin; Wayne Albers; Harish C Pant
Journal:  Eur J Biochem       Date:  2002-09

9.  Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity.

Authors:  Amy K Y Fu; Wing-Yu Fu; Alberto K Y Ng; Winnie W Y Chien; Yu-Pong Ng; Jerry H Wang; Nancy Y Ip
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

10.  Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.

Authors:  Fu-Ning Hsu; Mei-Chih Chen; Kuan-Chia Lin; Yu-Ting Peng; Pei-Chi Li; Eugene Lin; Ming-Ching Chiang; Jer-Tsong Hsieh; Ho Lin
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-08-13       Impact factor: 4.310

View more
  10 in total

1.  Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.

Authors:  David Askew; Tej K Pareek; Saada Eid; Sudipto Ganguly; Megan Tyler; Alex Y Huang; John J Letterio; Kenneth R Cooke
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

Review 2.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 3.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 4.  Immunomodulation by anticancer cell cycle inhibitors.

Authors:  Giulia Petroni; Silvia C Formenti; Selina Chen-Kiang; Lorenzo Galluzzi
Journal:  Nat Rev Immunol       Date:  2020-04-28       Impact factor: 53.106

Review 5.  Chromatin Remodeling Protein SMAR1 Is a Critical Regulator of T Helper Cell Differentiation and Inflammatory Diseases.

Authors:  Bhalchandra Mirlekar; Dipendra Gautam; Samit Chattopadhyay
Journal:  Front Immunol       Date:  2017-02-09       Impact factor: 7.561

Review 6.  Interferon Independent Non-Canonical STAT Activation and Virus Induced Inflammation.

Authors:  Yuchen Nan; Chunyan Wu; Yan-Jin Zhang
Journal:  Viruses       Date:  2018-04-14       Impact factor: 5.048

Review 7.  STAT3, a Master Regulator of Anti-Tumor Immune Response.

Authors:  Cédric Rébé; François Ghiringhelli
Journal:  Cancers (Basel)       Date:  2019-08-30       Impact factor: 6.639

Review 8.  Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.

Authors:  Ju-Ha Kim; Jisung Hwang; Ji Hoon Jung; Hyo-Jung Lee; Dae Young Lee; Sung-Hoon Kim
Journal:  Mol Cancer       Date:  2019-12-09       Impact factor: 27.401

9.  Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer.

Authors:  Kristina Witt; Susan Evans-Axelsson; Andreas Lundqvist; Martin Johansson; Anders Bjartell; Rebecka Hellsten
Journal:  Cancer Immunol Immunother       Date:  2021-03-31       Impact factor: 6.968

10.  STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle.

Authors:  Ethan L Morgan; Christopher W Wasson; Lucy Hanson; David Kealy; Ieisha Pentland; Victoria McGuire; Cinzia Scarpini; Nicholas Coleman; J Simon C Arthur; Joanna L Parish; Sally Roberts; Andrew Macdonald
Journal:  PLoS Pathog       Date:  2018-04-09       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.